Sushil Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sushil Kumar has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Asheesh Kumar Gupta
Faculty of Pharmacy, School of Pharmaceutical Sciences, IFTM University Delhi Road, NH-24 Moradabad, Lodhipur Rajpoot, Uttar Pradesh, 244102, India
3 shared publications- Shivam
Faculty of Pharmacy, School of Pharmaceutical Sciences, IFTM University Delhi Road, NH-24 Moradabad, Lodhipur Rajput, Uttar Pradesh, 244102, India
3 shared publications - Divya Chauhan
Department of Chemistry, School of Sciences, IFTM University, Moradabad (Uttar Pradesh), 244102, India
2 shared publications - Pooja Saini
School of Pharmaceutical Sciences, Faculty of Pharmacy, IFTM University, Moradabad, Uttar Pradesh, INDIA
2 shared publications - Shweta Verma
Faculty of Pharmacy, IFTM University, Lodhipur, Moradabad (UP) 244001, India
2 shared publications A.K. Wahi
Drug Design & Medicinal Chemistry Research Laboratory, College of Pharmacy, IFTM, Moradabad 244 001, U.P., India
1 shared publication
Latest Publications
- 1 June 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (21)
Emerging Lipid‐Based Nanoparticle Systems for Skin Cancer Therapy: Advancements, Challenges, and Future Perspectives
Skin cancer has become a major health concern with increasing incidence and mortality rates worldwide. In recent years, lipid‐based nanoparticles have emerged as novel therapeutic platforms for skin cancer therapy, offering enhanced biocompatibility, drug encapsulation capabilities, and targeted drug delivery to the tumor site. Clinical findings have suggested the ability of lipid nanoparticles to overcome skin and tumor microenvironment barriers, reduce systemic toxicity, and enhance drug accumulation at tumor sites. The objective of this review is to address and inspire future research and clinical adoption of lipid‐based nanotechnology, underscoring their potential to revolutionize precision skin cancer management through safer, more effective, and patient‐tailored interventions in the future. Various research and review articles were referred and compiled based on the literature from different electronic databases, including Google Scholar, ResearchGate, PubMed, Scopus, Web of Science, Embase, Elsevier, and Springer. This review provides detailed recent developments in formulation strategies, novel stimuli‐responsive and multifunctional systems, and surface modifications to improve specificity to tumor cells and their therapeutic outcomes. Lipid nanoparticles can revolutionize the future of skin cancer therapy and diagnosis. As clinical trials progress, more effective and personalized therapies are expected to emerge.
- 1 June 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (21)
Emerging Lipid‐Based Nanoparticle Systems for Skin Cancer Therapy: Advancements, Challenges, and Future Perspectives
Skin cancer has become a major health concern with increasing incidence and mortality rates worldwide. In recent years, lipid‐based nanoparticles have emerged as novel therapeutic platforms for skin cancer therapy, offering enhanced biocompatibility, drug encapsulation capabilities, and targeted drug delivery to the tumor site. Clinical findings have suggested the ability of lipid nanoparticles to overcome skin and tumor microenvironment barriers, reduce systemic toxicity, and enhance drug accumulation at tumor sites. The objective of this review is to address and inspire future research and clinical adoption of lipid‐based nanotechnology, underscoring their potential to revolutionize precision skin cancer management through safer, more effective, and patient‐tailored interventions in the future. Various research and review articles were referred and compiled based on the literature from different electronic databases, including Google Scholar, ResearchGate, PubMed, Scopus, Web of Science, Embase, Elsevier, and Springer. This review provides detailed recent developments in formulation strategies, novel stimuli‐responsive and multifunctional systems, and surface modifications to improve specificity to tumor cells and their therapeutic outcomes. Lipid nanoparticles can revolutionize the future of skin cancer therapy and diagnosis. As clinical trials progress, more effective and personalized therapies are expected to emerge.
- 1 October 2025
- Published by Bentham Science Publishers Ltd. in The Natural Products Journal
- Vol. 15 (7) , 1-22
Diabetic Nephropathy: Advancement in Molecular Mechanism, Pathogenesis, and Management by Pharmacotherapeutics and Natural Compounds
The primary cause of End-stage Renal Disease (ESRD) and a possible chronic microvascular consequence of diabetes mellitus is Diabetic Nephropathy (DN). The early stages of diabetic kidney disease (DN) often include hyperfiltration and albuminuria, which are followed by a steady loss in renal function. Diabetes patients may display the usual signs and symptoms of Diabetic Kidney Disease (DKD), particularly if they have Type 2 Diabetes Mellitus (T2DM). Significant confounders might also include the presence of other glomerular/tubular illnesses and severe peripheral vascular disease. Patients with diabetic nephropathy have an all-cause mortality rate that is approximately thirty times higher than that of diabetic patients without nephropathy. Most patients with diabetic nephropathy die from cardiovascular disease before they develop End-stage Renal Disease (ESRD). The formation of diabetic nephropathy must be prevented and its advancement must be slowed by controlling metabolic and hemodynamic abnormalities. Research should concentrate on developing new therapies for diabetic nephropathy since it is a crippling condition that affects people worldwide and causes significant social and economic burdens. Recent findings suggest that numerous pathways are activated during diabetes mellitus and that these pathways individually or collectively play a role in the induction and progression of diabetic nephropathy. However, clinical strategies targeting these pathways to manage diabetic nephropathy remain unsatisfactory, as the number of diabetic patients with nephropathy is increasing yearly. To develop ground-breaking therapeutic options to prevent the development and progression of diabetic nephropathy, a comprehensive understanding of the molecular mechanisms involved in the pathogenesis of the disease is mandatory. Therefore, the purpose of this paper was to discuss the underlying mechanisms and downstream pathways involved in the pathogenesis of diabetic nephropathy.
- 1 October 2025
- Published by Bentham Science Publishers Ltd. in The Natural Products Journal
- Vol. 15 (7) , 1-22
Diabetic Nephropathy: Advancement in Molecular Mechanism, Pathogenesis, and Management by Pharmacotherapeutics and Natural Compounds
The primary cause of End-stage Renal Disease (ESRD) and a possible chronic microvascular consequence of diabetes mellitus is Diabetic Nephropathy (DN). The early stages of diabetic kidney disease (DN) often include hyperfiltration and albuminuria, which are followed by a steady loss in renal function. Diabetes patients may display the usual signs and symptoms of Diabetic Kidney Disease (DKD), particularly if they have Type 2 Diabetes Mellitus (T2DM). Significant confounders might also include the presence of other glomerular/tubular illnesses and severe peripheral vascular disease. Patients with diabetic nephropathy have an all-cause mortality rate that is approximately thirty times higher than that of diabetic patients without nephropathy. Most patients with diabetic nephropathy die from cardiovascular disease before they develop End-stage Renal Disease (ESRD). The formation of diabetic nephropathy must be prevented and its advancement must be slowed by controlling metabolic and hemodynamic abnormalities. Research should concentrate on developing new therapies for diabetic nephropathy since it is a crippling condition that affects people worldwide and causes significant social and economic burdens. Recent findings suggest that numerous pathways are activated during diabetes mellitus and that these pathways individually or collectively play a role in the induction and progression of diabetic nephropathy. However, clinical strategies targeting these pathways to manage diabetic nephropathy remain unsatisfactory, as the number of diabetic patients with nephropathy is increasing yearly. To develop ground-breaking therapeutic options to prevent the development and progression of diabetic nephropathy, a comprehensive understanding of the molecular mechanisms involved in the pathogenesis of the disease is mandatory. Therefore, the purpose of this paper was to discuss the underlying mechanisms and downstream pathways involved in the pathogenesis of diabetic nephropathy.
- Open Access
- 31 August 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (4) , 1255-1268
Molecular Docking Studies and In Silico ADMET Screening of New Chalcones as Lanosterol α-Demethylase and DNA Gyrase Topoisomerase B Inhibitors
Chalcone and their benzotriazole derivatives originate from the nucleus ability to interpose into DNA base pairs, which inhibit lanosterol α-demethylase and DNA gyrase topoisomerase B. The active sites of topoisomerase B and lanosterol are the sites of molecular docking studies that provide comprehension of the intermolecular interactions for antimicrobial activity. Docking and ADMET properties of designed substituted benzaldehyde chalcones and their benzotriazoles using Schrodinger suit-2024 Maestro and SwissADME software programs against lanosterol α-demethylase and DNA gyrase topoisomerase B. C. albicans (lanosterol α-demethylase, PDB ID:4WMZ) and E. Coli (DNA gyrase topoisomerase B, PDB ID:1KZN) were selected for their respective binding affinities based on interaction patterns, GLIDE scores and docking scores. Compounds (7B1-7B7 and 9B1-9B3) showed strong binding interactions, and their ability to inhibit lanosterol α-demethylase (4WMZ) and DNA gyrase topoisomerase B (1KZN) for antimicrobial activity. Among the compounds, 9B1, 9B2, 9B3, and 7B1 have good binding affinity with GLIDE scores in the range of -10.655 to -10.154 against C. albicans and 7B1, 7B2 and 9B2 have good binding affinity with GLIDE score in range of -5.613 to -5.083 against E. coli when compared with the standard Fluconazole (-6.58) and Amoxicillin (-5.29). Test compounds showed good ADMET properties and similarity with respect to standard drugs. Molecular docking studies and in silico ADMET screening of new chalcones and their benzotriazole derivatives could be used as inhibitors of lanosterol α-demethylase (4WMZ) and DNA gyrase topoisomerase B (1KZN). Additional in-vitro and in-vivo research could confirm its potential as antimicrobials.
- 31 August 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (4) , 1255-1268
Open AccessMolecular Docking Studies and In Silico ADMET Screening of New Chalcones as Lanosterol α-Demethylase and DNA Gyrase Topoisomerase B Inhibitors
Chalcone and their benzotriazole derivatives originate from the nucleus ability to interpose into DNA base pairs, which inhibit lanosterol α-demethylase and DNA gyrase topoisomerase B. The active sites of topoisomerase B and lanosterol are the sites of molecular docking studies that provide comprehension of the intermolecular interactions for antimicrobial activity. Docking and ADMET properties of designed substituted benzaldehyde chalcones and their benzotriazoles using Schrodinger suit-2024 Maestro and SwissADME software programs against lanosterol α-demethylase and DNA gyrase topoisomerase B. C. albicans (lanosterol α-demethylase, PDB ID:4WMZ) and E. Coli (DNA gyrase topoisomerase B, PDB ID:1KZN) were selected for their respective binding affinities based on interaction patterns, GLIDE scores and docking scores. Compounds (7B1-7B7 and 9B1-9B3) showed strong binding interactions, and their ability to inhibit lanosterol α-demethylase (4WMZ) and DNA gyrase topoisomerase B (1KZN) for antimicrobial activity. Among the compounds, 9B1, 9B2, 9B3, and 7B1 have good binding affinity with GLIDE scores in the range of -10.655 to -10.154 against C. albicans and 7B1, 7B2 and 9B2 have good binding affinity with GLIDE score in range of -5.613 to -5.083 against E. coli when compared with the standard Fluconazole (-6.58) and Amoxicillin (-5.29). Test compounds showed good ADMET properties and similarity with respect to standard drugs. Molecular docking studies and in silico ADMET screening of new chalcones and their benzotriazole derivatives could be used as inhibitors of lanosterol α-demethylase (4WMZ) and DNA gyrase topoisomerase B (1KZN). Additional in-vitro and in-vivo research could confirm its potential as antimicrobials.
- Open Access
- 20 December 2024
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 21 (4) , 1485-1493
Molecular Docking, Synthesis and In vivo Assessment of New Phenothiazines as Inhibitors of Anxiety
Background: Heterocylics are the backbone of the medicinal chemistry. They played very imperative role in the discovery of new lead molecules. Phenothiazine is one of them and it has many biological activities as well. This article proposed the design and synthesis of new phenothiazine derivatives. Aim: This work includes the preparation of some new Schiff bases of phenothiazine. The synthetic scheme includes development of series of 1-(10H-phenothiazin-10-yl)-2-(4-((phenylimino)methyl) phenoxy) ethan-1-one (D1-D10). Objective: This work aims to design some new phenothiazine molecules. Phenothiazine is main heterocyclic moiety of this work to perform their computational study and to evaluate the prepared molecules as anxiolytic agents. Result: All the derivatives was synthesized in the laboratory and characterized by applying different parameters. These parameters include melting point, solubility, Rf value, spectroscopic analysis like IR spectroscopy and 1H-NMR spectroscopy. Some software was used to dock the derivatives and to perform the computational studies. Conclusion: The synthesized compounds were screened for anti-anxiety activity and elevated plus maze method was incorporated to perform the activity. Statistical analysis of the prepared derivatives was done followed by one way ANOVA dunnett’s test. Among them, some derivatives showed potent activity and some showed moderate activity against anxiety.
- 20 December 2024
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 21 (4) , 1485-1493
Open AccessMolecular Docking, Synthesis and In vivo Assessment of New Phenothiazines as Inhibitors of Anxiety
Background: Heterocylics are the backbone of the medicinal chemistry. They played very imperative role in the discovery of new lead molecules. Phenothiazine is one of them and it has many biological activities as well. This article proposed the design and synthesis of new phenothiazine derivatives. Aim: This work includes the preparation of some new Schiff bases of phenothiazine. The synthetic scheme includes development of series of 1-(10H-phenothiazin-10-yl)-2-(4-((phenylimino)methyl) phenoxy) ethan-1-one (D1-D10). Objective: This work aims to design some new phenothiazine molecules. Phenothiazine is main heterocyclic moiety of this work to perform their computational study and to evaluate the prepared molecules as anxiolytic agents. Result: All the derivatives was synthesized in the laboratory and characterized by applying different parameters. These parameters include melting point, solubility, Rf value, spectroscopic analysis like IR spectroscopy and 1H-NMR spectroscopy. Some software was used to dock the derivatives and to perform the computational studies. Conclusion: The synthesized compounds were screened for anti-anxiety activity and elevated plus maze method was incorporated to perform the activity. Statistical analysis of the prepared derivatives was done followed by one way ANOVA dunnett’s test. Among them, some derivatives showed potent activity and some showed moderate activity against anxiety.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 24 (3) , 264-280
Current Concepts in the Molecular Mechanisms and Management of Diabetic Neuropathy by Pharmacotherapeutics and Natural Compounds
: One of the most crippling effects of diabetes mellitus is diabetic neuropathy, which can cause discomfort, loss of movement, and even amputation. Diabetic neuropathy manifests in a variety of ways, ranging from pain to death. Diagnosing diabetic neuropathy can be challenging since it often goes unnoticed for many years following the onset of diabetes. In addition to oxidative stress in neurons, hyperglycemia activates a number of metabolic pathways that are important sources of damage and possible targets for treatment in diabetic neuropathy. Downstream metabolic cascades caused by prolonged hyperglycemia include activation of protein kinase C, increased production of advanced glycation end products, excessive release of cytokines, increased oxidative stress, and injury to peripheral nerves. Despite the fact that these metabolic anomalies are considered the main cause of diabetes-related microvascular issues, the diverse mechanistic processes of neuropathy are characterized by organ-specific histological and biochemical features. Although the symptoms of diabetic neuropathy can be treated, there are few options to correct the underlying problem. Diabetic neuropathy exerts a tremendous financial, psychological, and physical burden on society, emphasizing the need for efficient and focused treatment. The major goal of this review is to shed light on the multiple mechanisms and pathways that contribute to the onset of diabetic neuropathy and to provide readers with a comprehensive understanding of emerging therapeutic strategies to postpone or reverse various forms of diabetic neuropathy. The article discusses available medications and provides the latest guidelines for the treatment of pain and distal symmetric polyneuropathy, including diabetic autonomic neuropathy, which may help the patients control pain well and assess alternatives for treatment that might be more successful in preventing or delaying the course of a disease.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 24 (3) , 264-280
Current Concepts in the Molecular Mechanisms and Management of Diabetic Neuropathy by Pharmacotherapeutics and Natural Compounds
: One of the most crippling effects of diabetes mellitus is diabetic neuropathy, which can cause discomfort, loss of movement, and even amputation. Diabetic neuropathy manifests in a variety of ways, ranging from pain to death. Diagnosing diabetic neuropathy can be challenging since it often goes unnoticed for many years following the onset of diabetes. In addition to oxidative stress in neurons, hyperglycemia activates a number of metabolic pathways that are important sources of damage and possible targets for treatment in diabetic neuropathy. Downstream metabolic cascades caused by prolonged hyperglycemia include activation of protein kinase C, increased production of advanced glycation end products, excessive release of cytokines, increased oxidative stress, and injury to peripheral nerves. Despite the fact that these metabolic anomalies are considered the main cause of diabetes-related microvascular issues, the diverse mechanistic processes of neuropathy are characterized by organ-specific histological and biochemical features. Although the symptoms of diabetic neuropathy can be treated, there are few options to correct the underlying problem. Diabetic neuropathy exerts a tremendous financial, psychological, and physical burden on society, emphasizing the need for efficient and focused treatment. The major goal of this review is to shed light on the multiple mechanisms and pathways that contribute to the onset of diabetic neuropathy and to provide readers with a comprehensive understanding of emerging therapeutic strategies to postpone or reverse various forms of diabetic neuropathy. The article discusses available medications and provides the latest guidelines for the treatment of pain and distal symmetric polyneuropathy, including diabetic autonomic neuropathy, which may help the patients control pain well and assess alternatives for treatment that might be more successful in preventing or delaying the course of a disease.
- 1 March 2024
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 21 (2) , 1
Acute Oral Toxicity, Antioxidant Activity and Molecular Docking Study of 2-(4-Bromo-phenoxy)-N-[6-chloro-4-(4-chlorophenyl)-3-cyano-4H-chromen- 2-yl]-acetamide
Background: Several studies have been conducted on 4-H chromene compounds because of their intriguing pharmacological and biological properties. Various new natural compounds having a chromene foundation have been reported over the past 20 years. Objective: In the present study, we reported the acute oral toxicity, antioxidant activity, and molecular docking study of the most active 4H-chromene derivative2-(4-Bromo-phenoxy)-N-[6-chloro-4-(4- chlorophenyl)-3-cyano-4H-chromen-2-yl]-acetamide (A9). Method: The acute oral toxicity was carried out as per OECD 423 guidelines. For investigating the antioxidant activity, various biochemical parameters in colon tissue like SOD, CAT, MDA, PC and GSH and also enzyme levels, such as ALT, AST, ALP, and LDH, were measured in this experiment. Results: Acute oral toxicity study indicated that the A9 ligand was found to be safer in animals. Additionally, the A9 ligand had significant antioxidant properties at various doses and was not found to be harmful to the liver. Due to its stronger binding energy and the appropriate interactions that induce inhibition, the A9 ligand's antioxidant function was also validated by additional molecular docking research. Conclusion: This compound can be exploited as a lead molecule in further research.
- 1 March 2024
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 21 (2) , 1
Acute Oral Toxicity, Antioxidant Activity and Molecular Docking Study of 2-(4-Bromo-phenoxy)-N-[6-chloro-4-(4-chlorophenyl)-3-cyano-4H-chromen- 2-yl]-acetamide
Background: Several studies have been conducted on 4-H chromene compounds because of their intriguing pharmacological and biological properties. Various new natural compounds having a chromene foundation have been reported over the past 20 years. Objective: In the present study, we reported the acute oral toxicity, antioxidant activity, and molecular docking study of the most active 4H-chromene derivative2-(4-Bromo-phenoxy)-N-[6-chloro-4-(4- chlorophenyl)-3-cyano-4H-chromen-2-yl]-acetamide (A9). Method: The acute oral toxicity was carried out as per OECD 423 guidelines. For investigating the antioxidant activity, various biochemical parameters in colon tissue like SOD, CAT, MDA, PC and GSH and also enzyme levels, such as ALT, AST, ALP, and LDH, were measured in this experiment. Results: Acute oral toxicity study indicated that the A9 ligand was found to be safer in animals. Additionally, the A9 ligand had significant antioxidant properties at various doses and was not found to be harmful to the liver. Due to its stronger binding energy and the appropriate interactions that induce inhibition, the A9 ligand's antioxidant function was also validated by additional molecular docking research. Conclusion: This compound can be exploited as a lead molecule in further research.
- 1 January 2024
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 20 (1) , 1
Review on In-vitro Techniques and In-vivo Animals Models for Screening Diabetes and Diabetic Complications
Diabetes mellitus is a type of metabolic disorders. Various pharmaceutical interventions and animal models have been used to investigate the genetic, environmental, and etiological aspects of diabetes and its effects. In recent years for the development of ant-diabetic remedies, numerous novel genetically modified animals, pharmaceutical substances, medical techniques, viruses, and hormones have been developed to screen diabetic complications. A unique disease-treating drug with new properties is still being sought after. The current review tried to include all published models and cutting-edge techniques. Experimental induction of diabetes mellitus in animal models and in vitro methods are essential for advancing our knowledge, a thorough grasp of pathophysiology, and the creation of novel therapeutics. Animal models and in vitro techniques are necessary to develop innovative diabetic medications. New approaches and additional animal models are required for diabetes research to advance. This is particularly true for models produced via dietary modifications, which have various macronutrient compositions. In this article, we review the rodent models of diet-induced diabetic peripheral neuropathy, diabetic retinopathy, and diabetic nephropathy and critically compare the key characteristics of these micro-vascular complications in humans and the diagnostic criteria with the parameters used in preclinical research using rodent models, taking into consideration the potential need for factors that can accelerate or aggravate these conditions.
- 1 January 2024
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 20 (1) , 1
Review on In-vitro Techniques and In-vivo Animals Models for Screening Diabetes and Diabetic Complications
Diabetes mellitus is a type of metabolic disorders. Various pharmaceutical interventions and animal models have been used to investigate the genetic, environmental, and etiological aspects of diabetes and its effects. In recent years for the development of ant-diabetic remedies, numerous novel genetically modified animals, pharmaceutical substances, medical techniques, viruses, and hormones have been developed to screen diabetic complications. A unique disease-treating drug with new properties is still being sought after. The current review tried to include all published models and cutting-edge techniques. Experimental induction of diabetes mellitus in animal models and in vitro methods are essential for advancing our knowledge, a thorough grasp of pathophysiology, and the creation of novel therapeutics. Animal models and in vitro techniques are necessary to develop innovative diabetic medications. New approaches and additional animal models are required for diabetes research to advance. This is particularly true for models produced via dietary modifications, which have various macronutrient compositions. In this article, we review the rodent models of diet-induced diabetic peripheral neuropathy, diabetic retinopathy, and diabetic nephropathy and critically compare the key characteristics of these micro-vascular complications in humans and the diagnostic criteria with the parameters used in preclinical research using rodent models, taking into consideration the potential need for factors that can accelerate or aggravate these conditions.
- Open Access
- 30 October 2023
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 39 (5) , 1232-1238
Synthesis, Characterization, Molecular docking and Anti-anxiety Evaluation of Some Novel Phenothiazine Derivatives
The phenothiazine derivatives 1-(10H-phenothiazin-10-yl)-2-(4-(1-(phenylimino)ethyl)phenoxy)ethan-1-one (4a-4j) are produced from 2-(4-acetylphenoxy)-1-(10H-phenothiazin-10-yl)ethan-1-one (3) and after that, condensing them with various carbonyl compounds. Acetonitrile was used as solvent. The purity of the analogues and reaction progress were identified through their retention factor value and melting point. Characterization of the prepared analogues was completed via performing their Infra-red, proton-nuclear magnetic resonance spectroscopy with their elemental analysis. The set of molecular docking parameters of the compounds were assessed to check to their potentiality. Autodock Vina 1.2.0 was used to dock the derivatives and the docking score of all the synthesized derivatives ranges from -8.7 to -10.2. Investigation of anti-anxiety activity on albino wistar rat, was executed for all the prepared phenothiazine analogues. EPM model was approached for performing anti-anxiety study, taking Diazepam as standard drug. The compounds 2-(4-(1-((3-nitrophenyl) imino)ethyl)phenoxy)-1-(10H-phenothiazin-10-yl)ethan-1-one (4e) and 2-(4-(1-((3,4-dinitrophenyl)imino)ethyl)phenoxy)-1-(10H-phenothiazin-10-yl)ethan-1-one (4g) were showed maximum potency among all the prepared derivatives as compared to Diazepam.
- 30 October 2023
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 39 (5) , 1232-1238
Open AccessSynthesis, Characterization, Molecular docking and Anti-anxiety Evaluation of Some Novel Phenothiazine Derivatives
The phenothiazine derivatives 1-(10H-phenothiazin-10-yl)-2-(4-(1-(phenylimino)ethyl)phenoxy)ethan-1-one (4a-4j) are produced from 2-(4-acetylphenoxy)-1-(10H-phenothiazin-10-yl)ethan-1-one (3) and after that, condensing them with various carbonyl compounds. Acetonitrile was used as solvent. The purity of the analogues and reaction progress were identified through their retention factor value and melting point. Characterization of the prepared analogues was completed via performing their Infra-red, proton-nuclear magnetic resonance spectroscopy with their elemental analysis. The set of molecular docking parameters of the compounds were assessed to check to their potentiality. Autodock Vina 1.2.0 was used to dock the derivatives and the docking score of all the synthesized derivatives ranges from -8.7 to -10.2. Investigation of anti-anxiety activity on albino wistar rat, was executed for all the prepared phenothiazine analogues. EPM model was approached for performing anti-anxiety study, taking Diazepam as standard drug. The compounds 2-(4-(1-((3-nitrophenyl) imino)ethyl)phenoxy)-1-(10H-phenothiazin-10-yl)ethan-1-one (4e) and 2-(4-(1-((3,4-dinitrophenyl)imino)ethyl)phenoxy)-1-(10H-phenothiazin-10-yl)ethan-1-one (4g) were showed maximum potency among all the prepared derivatives as compared to Diazepam.
- 1 January 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 20 (1) , 1
Synthesis and Biological Evaluation of Some New Chalcone Derivatives as Anti-inflammatory Agents
Aim: The present research work aims to prepare a series of 1-(4-(2-(1H-indol-1-yl)-2- oxoethoxy)phenyl)-3-phenylprop-2-en-1-one derivatives. Method: The major compound was achieved by the reaction of indole with chloroacetylchloride in benzene afforded 2-chloro-1-(indoline-1-yl) ethanone which reacts o- hydroxy acetophenone in presence of acetonitrile to form 2-(4-acetylphenoxy)-1-(1H-indol-1-yl)ethan-1-one then goes through aldol condensation to give various final derivatives. Results and conclusion: After the synthesis of compounds, the synthesized compounds were characterized by checking their solubility, melting point, thin layer chromatography, IR, 1HNMR spectral data and elemental analysis. All of the prepared derivatives were evaluated for their anti-inflammatory activity on wistar albino rats by following the carrageenan-induced Rat Hind Paw Edema model.
- 1 January 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Discovery Technologies
- Vol. 20 (1) , 1
Synthesis and Biological Evaluation of Some New Chalcone Derivatives as Anti-inflammatory Agents
Aim: The present research work aims to prepare a series of 1-(4-(2-(1H-indol-1-yl)-2- oxoethoxy)phenyl)-3-phenylprop-2-en-1-one derivatives. Method: The major compound was achieved by the reaction of indole with chloroacetylchloride in benzene afforded 2-chloro-1-(indoline-1-yl) ethanone which reacts o- hydroxy acetophenone in presence of acetonitrile to form 2-(4-acetylphenoxy)-1-(1H-indol-1-yl)ethan-1-one then goes through aldol condensation to give various final derivatives. Results and conclusion: After the synthesis of compounds, the synthesized compounds were characterized by checking their solubility, melting point, thin layer chromatography, IR, 1HNMR spectral data and elemental analysis. All of the prepared derivatives were evaluated for their anti-inflammatory activity on wistar albino rats by following the carrageenan-induced Rat Hind Paw Edema model.
- 21 September 2021
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 17 (4) , 504-510
Pharmacophore Generation, Quantitative Structure-Activity Relationship (QSAR), and Molecular Dynamic Simulation of Newly Substituted N-(6- Chloro-3-cyano-4-phenyl-4H-chromen-2-yl)-2-(4-chloro-phenoxy)-acetamide for Anticancer Activity
Aim and Objective: The main objective of the study was to develop the Quantitative Structure Activity Relationship (QSAR) and pharmacophoric model by using data obtained from HT-29 cells study for the scientific community to develop potent lead molecule. Materials and Methods: Common pharmacophore model, atom-based 3D-QSAR, and molecular dynamic (MD) simulation were carried out via computational techniques by using 4Hchromene derivatives. Results: The reliable common pharmacophoric hypothesis, DHH13 was generated and 3.95 survival values were also found. Furthermore, the statistically significant of 3D-QSAR model was developed where we have found the r2=0.52 by using Partial least squares (PLS) regression method. Phase predicted activity and Log GI50 were demonstrated the mainly important atomic position in the backbone structure of ligands in order to ascertain anticolon cancer activity. In addition, MD simulation was carried out between top rank lead with IL-6 target which provided and also defined the better binding conformational and complex stability into the active pocket of target throughout the MD simulation. Conclusion: The final outcome from this design approach shows that the pharmacophoric model and 3D-QSAR might be helpful in the medicinal chemistry field for the researcher to develop the potential anticolon cancer compounds.
- 21 September 2021
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 17 (4) , 504-510
Pharmacophore Generation, Quantitative Structure-Activity Relationship (QSAR), and Molecular Dynamic Simulation of Newly Substituted N-(6- Chloro-3-cyano-4-phenyl-4H-chromen-2-yl)-2-(4-chloro-phenoxy)-acetamide for Anticancer Activity
Aim and Objective: The main objective of the study was to develop the Quantitative Structure Activity Relationship (QSAR) and pharmacophoric model by using data obtained from HT-29 cells study for the scientific community to develop potent lead molecule. Materials and Methods: Common pharmacophore model, atom-based 3D-QSAR, and molecular dynamic (MD) simulation were carried out via computational techniques by using 4Hchromene derivatives. Results: The reliable common pharmacophoric hypothesis, DHH13 was generated and 3.95 survival values were also found. Furthermore, the statistically significant of 3D-QSAR model was developed where we have found the r2=0.52 by using Partial least squares (PLS) regression method. Phase predicted activity and Log GI50 were demonstrated the mainly important atomic position in the backbone structure of ligands in order to ascertain anticolon cancer activity. In addition, MD simulation was carried out between top rank lead with IL-6 target which provided and also defined the better binding conformational and complex stability into the active pocket of target throughout the MD simulation. Conclusion: The final outcome from this design approach shows that the pharmacophoric model and 3D-QSAR might be helpful in the medicinal chemistry field for the researcher to develop the potential anticolon cancer compounds.